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Abstract: The transcription factor signal transducer and activator of transcription (STAT)3 mediates
the functions of cytokines, growth factors, and oncogenes under both physiological and pathological
conditions. Uncontrolled/constitutive STAT3 activity is often detected in tumors of different types,
where its role is mostly that of an oncogene, contributing in multiple ways to tumor transformation,
growth, and progression. For this reason, many laboratories and pharmaceutical companies are
making efforts to develop specific inhibitors. However, STAT3 has also been shown to act as a tumor
suppressor in a number of cases, suggesting that its activity is strongly context-specific. Here,
we discuss the bases that can explain the multiple roles of this factor in both physiological and
pathological contexts. In particular, we focus on the following four features: (i) the distinct properties
of the STAT3α and β isoforms; (ii) the multiple post-translational modifications (phosphorylation
on tyrosine or serine, acetylation and methylation on different residues, and oxidation and
glutathionylation) that can affect its activities downstream of multiple different signals; (iii) the
non-canonical functions in the mitochondria, contributing to the maintenance of energy homeostasis
under stress conditions; and (iv) the recently discovered functions in the endoplasmic reticulum,
where STAT3 contributes to the regulation of calcium homeostasis, energy production, and apoptosis.
Keywords: STAT3; post-translational modifications; endoplasmic reticulum; mitochondrial associated
membranes (MAMs), nucleus; apoptosis; cancer
1. Introduction
Signal transducer and activator of transcription (STAT) factors are activated by tyrosine
phosphorylation, mainly by receptor-associated Janus kinases (JAKs) downstream of cytokine and
growth factor receptors [1,2]. Tyrosine-phosphorylated (YP)-STATs active dimers, formed by reciprocal
SH2 domain-phosphotyrosine interaction, concentrated in the nucleus to regulate the expression
of target genes [3]. The ubiquitously expressed STAT3 family member is canonically activated
by YP downstream of a wide variety of cytokines, including those of the interleukin-6 (IL-6)
family, leptin, IL-12, IL-17, and IL-10, as well as interferons; growth factors, such as granulocyte
colony-stimulating factor (G-CSF), epidermal growth factor (EGF), platelet-derived growth factor
(PDGF), and oncogenes like Src, Abl, Sis, Fps, Ros, Met, and ErbB2 [4–6]; G protein coupled receptors
like the sphingosine-1-phosphate receptor (S1PR)1; and Toll-like receptors (for recent reviews, see [6,7]).
Accordingly, STAT3 is known to play a multitude of distinct and sometimes even contradictory
functions in different cell types, both under physiological and pathological conditions. It is thus
not surprising that STAT3 gene inactivation, which is unlikely for that of all other STAT genes,
is early embryonic lethal [8]. Indeed, STAT3 plays an important role in cell growth and survival.
Among its numerous functions are the induction of liver acute-phase response genes and of liver
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regeneration [9,10], the stimulation of B lymphocytes differentiation [11], the regulation of the activity
of many hematopoietic cells subsets [12–17], the induction of lysosome-mediated apoptosis during
mammary gland involution [18], the protection from apoptosis and heart infarction [19], and the
maintenance of pluripotency in embryonic stem cells [20]. Most of these functions were exhaustively
described in recent reviews, including some published as part of this Special Issue [21–27].
The activation/inactivation of STAT proteins is a crucial step for their biological activities, and the
disruption of this control, leading to defective or constitutive STATs activation, usually correlates with
the development of pathological conditions. Accordingly, STAT3 activation must be tightly controlled
by negative regulators, which mainly belong to three groups, namely: phosphatases, suppressor of
cytokine signaling (SOCS) proteins, and the protein inhibitor of activated STAT (PIAS) proteins [28–30].
Phosphatases, like SHP-1, SHP-2, and PTP1B, directly counteract JAK-mediated phosphorylation,
whereas nuclear phosphatases, such as T-cell PTP, play a role in signal termination [28]. SOCS genes,
and in particular SOCS3, are direct STAT3 target genes and act as negative feedback regulators by
triggering the proteasomal degradation of JAK kinases [31]. Finally, PIAS3 prevents the binding of
STAT3 to its target DNA [32].
2. STAT3 as a Conditional Oncogene
In agreement with the observation that most of its numerous activators/negative regulators are
frequently deregulated in cancer, STAT3 is frequently constitutively activated in many tumors both
of hematopoietic and epithelial origin, and is mostly considered as an oncogene (recently reviewed
in the literature [6,7,21]). Activating mutations are also detected, mostly in lymphoid tumors [33–35].
Importantly, both the transcriptional and non-transcriptional activities of STAT3 can promote
tumorigenesis. Indeed, STAT3 transcriptional functions are required for tumor transformation by
oncogenes that trigger its YP, such as, for example, Src [36]. On the other hand, STAT3 is also required
for Ras-mediated transformation, independently of YP and transcriptional activity [37].
The STAT3 constitutive activity in tumors can induce proliferation and resistance to apoptosis,
down-modulate immune responses and promote angiogenesis, enhance invasion and metastasis by
inducing epithelial to mesenchymal transition (EMT), alter the extracellular matrix inducing matrix
metalloproteinases (MMP) and promote collagen cross-linking and tissue tension, regulate energy
metabolism and mitochondrial activity, and confer cancer stem cell features in a number of liquid and
solid tumors [7,38–41]. Finally, STAT3 activity is also crucial to determine the pro-tumorigenic features
of most tumor stromal cells [21].
However, in keeping with the complexity of its functions, recent evidence is accumulating that
STAT3 can also act as a tumor suppressor under specific conditions (recently reviewed in [21]),
even in tumors where it was previously shown to play pro-oncogenic functions. For example,
STAT3 could inhibit glial tumor growth downstream of mutations of PTEN, but not of type III
epidermal growth factor receptor (EGFRvIII) [42]; help bypass senescence in prostate cancer [43];
suppress tumor development by impairing the expression of IL-8 and thus the recruitment of myeloid
cells in kirsten rat sarcoma viral oncogene homolog (K-RAS) mutant lung adenocarcinomas [44];
impair tumor progression in APC mutant colon cancer but not in inflammation-driven colorectal
carcinogenesis [45–48]; and impair tumor cell proliferation in thyroid carcinomas [49]. Thus, it appears
that the STAT3 functions in cancer can vary according to context, genetic background, and phase of
the tumor.
3. STAT3 Multifaceted Functions: How, Where, and When?
Certainly, the multiple and even contrasting actions of STAT3 both under physiological and
pathological conditions can be partly explained by its ability to activate different target genes in
different cell types and under different conditions. This is in turn due to the cell- and context-specific
accessibility of STAT3 binding sites on the genome [50], to its ability to interact with other transcription
factors, and with distinct co-factors modulating or redirecting their activity (see [7,25,51], for recent
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reviews). Also relevant is the above discussed convergence of multiple signaling pathways on STAT3,
which determines the STAT3 activation in many different contexts and downstream of multiple stimuli.
On the other hand, referring to STAT3 as a single factor is somewhat misleading. Indeed,
STAT3 exists in two alternatively spliced isoforms, the full length STAT3α and the truncated STAT3β,
which possess both specific and overlapping transcriptional activities [52–54]. Additionally, STAT3 can
be post-translationally modified in a number of alternative ways in addition to YP, variably affecting
its activity and cellular localization (Figure 1). The main features of the α and β isoforms and of the
known post-translational modifications are summarized below.
Figure 1. The scheme depicts the multiple roles of signal transducer and activator of transcription
(STAT)3 according to its post-translational modifications and subcellular localization. See text for
details and references. YP—tyrosine-phosphorylated (YP)-STATs; SP—serine phosphorylation.
3.1. STAT3α and STAT3β
While STAT3α is the full-length form of STAT3, the β isoform lacks the C-terminal transcriptional
activation domain (TAD) including S727, replaced by a unique seven amino acid tail [55,56]. STAT3β,
which can thus get phosphorylated on Y705, and dimerize and bind to DNA, but cannot get
phosphorylated on S727, has long been considered as a dominant negative form [55]. However, several
works have established that STAT3β plays unique functions, activating sets of specific target genes.
Notably, this isoform can alone sustain embryonal development, resulting in the post-natal death
of mice specifically lacking the α isoform, in contrast to the early embryonal lethality of a complete
STAT3 inactivation [52–54]. As recently reviewed by Aigner et al. [57], STAT3α and β apparently play
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the opposite functions in tumorigenesis. While STAT3α appears to be responsible for most, if not all,
the pro-oncogenic activities ascribed to STAT3 [57], STAT3β can oppose these, acting as a dominant
negative form [38]. In contrast however, STAT3β can behave as an oncogene, inducing T-cell leukemia
development when overexpressed in transplanted bone marrow cells [58]. One of the main functions of
STAT3β, however, appears to be the suppression of systemic inflammation. Indeed, STAT3β null mice
are exquisitely sensitive to endotoxic shock [52,53], and develop exacerbated atherosclerosis in the
absence of ApoE [59]. Consistent with this anti-inflammatory role, the mice lacking STAT3β undergo
exacerbated acute inflammatory responses to irritants such as 12-O-Tetradecanoylphorbol-13-acetate
(TPA) and dextran sodium sulfate (DSS), resulting in accelerated skin and intestinal tumorigenesis
in the well-known TPA/DMBA and AOM/DSS models of inflammation-driven carcinogenesis [60].
Despite this, further tumor development is unchanged with respect to wild type mice, suggesting
that STAT3β is important in maintaining tissue homeostasis, playing an anti-oncogenic role in
inflammation-driven cancer mainly during the early steps of tumor formation. Thus, the balance
between the two STAT3 isoforms, in turn dictated by the specific signals determining the tumor
transformation and progression, and shaping the tumor microenvironment, is apparently crucial to
determine the initial tumor transformation rates in inflammation-associated cancers. Unfortunately,
very little information, if any, is available on the presence of other outstanding modifications that have
been detected and characterized on the STAT3α isoform (see below).
3.2. Tyrosine Phosphorylation
As already mentioned, STAT3 canonical activity as a transcription factor is mainly due to
phosphorylation on Y705, which determines the ability to form functional dimers, to concentrate
in the nucleus, and to bind DNA. This occurs downstream of the many activatory signals mentioned
above, and is in turn controlled by the negative regulators that lead to STAT3 dephosphorylation.
However, similar to STAT1, STAT3 can regulate transcription also when not phosphorylated. Indeed,
unphosphorylated (U)-STAT3 can shuttle between the nucleus and the cytoplasm [61], and has been
shown to be able to interact with other factors and to directly or indirectly bind to DNA on binding
sites distinct from the canonical gamma interferon activation site (GAS) sequences, thus exerting
its control on a different subset of target genes, including several oncogenes [62–64]. Accordingly,
high nuclear levels of U-STAT3 correlate with bad prognosis in glioblastoma [65]. The multiple so
called “canonical” functions of nuclear and YP STAT3 have been amply reviewed elsewhere, and will
not be discussed here [7,39,66].
In addition to its prevalent nuclear localization and function, YP-STAT3 has also been shown to
localize to the focal adhesions in ovarian cancer cells, where it interacts with phosphorylated paxillin
and focal adhesion kinase (FAK), thus regulating cell migration [67]. STAT3 can regulate cell migration
also from the cytoplasm, where its non-phosphorylated form inhibits the microtubule-destabilizing
protein stathmin, resulting in enhanced microtubules polymerization and cell migration [68]. Moreover,
always in the cytoplasm, likely non-phosphorylated STAT3 can interact with protein kinase R (PKR),
blocking its enzymatic activity and thus inhibiting autophagy [69]. This association is inhibited by
fatty acids like palmitate, which leads to stimulation of the autophagic flux [69,70].
3.3. Serine Phosphorylation (SP)
In addition to YP, STAT3 can undergo a number of different post-translational modifications
correlated with either enhanced or reduced trans-activating potential. These can however also
regulate non-transcriptional functions of this factor. The first of these modifications to be detected is
phosphorylation on the serine residue in position 727 (SP), located in the carboxy-terminal transcriptional
activation domain and thus lacking in the STAT3β isoform. SP can be carried out by several
kinases including MAP kinases, PKCε and mTOR, downstream of both classical STAT3 activating
cytokines/growth factors, of the PI3 kinases and of Ras proteins [71,72]. While SP is required for the
optimal transcriptional induction of a subset of target genes [73], it can also modify STAT3 activation
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dynamics by inhibiting the subsequent YP [71]. More recently, it became clear that SP can confer specific
activities to STAT3 independently of YP, and not involving either nuclear localization or transcriptional
activity. In particular, SP-STAT3 drives important functions in the mitochondria [37], as better detailed in
the following sections (recently reviewed by Garama and Gough [74], and by Rincon [26]).
3.4. Acetylation
In response to cytokines and growth factors signaling, STAT3 can also be acetylated (Ac) on
multiple lysine (K) residues by the CBP/p300 histone acetyltransferase. K685 acetylation can enhance
the STAT3 transcriptional activity by increasing tyrosine phosphorylation and dimer stability [75],
and K685-acetylated STAT3 was shown to silence the tumor suppressor genes by recruiting DNA
methyltransferase 1 to their promoters [76]. In contrast, K87 acetylation downstream of the insulin
stimulation can promote STAT3 mitochondrial translocation and functions [77]. The nicotinamide
adenine dinucleotide (NAD)-dependent silent information regulator protein (SIRT)1 has been
shown to be able to deacetylate STAT3 [78]. SIRT1-mediated deacetylation leads both to reduced
YP/transcriptional activity and to decreased mitochondrial localization and function of SP-STAT3 [79].
3.5. Methylation
STAT3 methylation can occur in the nucleus on residues K140 or K180, with different effects on its
activities. The histone methyltransferase SET9 is able to methylate promoter-bound STAT3 on K140,
leading to impaired transcriptional activation of the target genes [80]. In contrast, the EZH2 component
of the polycomb complex 2 operates K180 tri-methylation, which was shown to be required to maintain
STAT3 YP and transcriptional activity in the cells from glioblastoma and prostate cancer [81].
3.6. Oxidation and Glutathionylation
Finally, STAT3 can become both oxidized and glutathionylated on multiple cysteine residues,
impairing its transcriptional activity, either under conditions of oxidative stress or downstream of
IL-6 signaling, which can raise reactive oxygen species (ROS) levels [82–85]. In contrast, mild ROS
production downstream of insulin-like growth factor 1 (IGF1), EGF, and other growth factors can
activate JAK kinases and enhance STAT3 YP and nuclear activity [86–89]. STAT3 oxidation can
occur downstream of the cytoplasmic thiol peroxidase peroxiredoxin-2 (Prx2), one of the major H2O2
scavengers within the cell [85]. This achieves ROS detoxification while at the same time impairing
IL-6-induced, STAT3-mediated transcription, suggesting that STAT3 is part of a redox relay controlling
redox homeostasis, and ROS and cytokine signaling. Indeed, the expression of a redox-insensitive
cysteine mutant STAT3 leads to increased STAT3 activity and cell growth rates. Therefore, this cross-talk
between oxidative and non-oxidative STAT3 modifications can affect the activities of YP-STAT3 as
well as cell proliferation and survival. Whether oxidation can also affect the activity of other modified
STAT3 forms is presently unknown. The complex functions of STAT3 in redox homeostasis were
recently reviewed [21,90].
4. Both Nuclear and Mitochondrial STAT3 Affect Energy Metabolism and Cellular Respiration
Tumor cells are known to rely on the so-called Warburg effect for their growth on metabolic
rewiring [91] involving, among others, a switch in glucose metabolism consisting of increased
aerobic glycolysis and reduced mitochondrial activity [92]. Although well known for many decades,
only recently was this switch explained alongside the need for rapidly growing cells to use lactate
as a building block for rapid macromolecules synthesis. Indeed, while glycolysis is energetically
less favorable because of the lower moles of ATP produced per mole of glucose, provided that the
glucose supply is not in shortage, glycolysis is faster than aerobic respiration. Moreover, lactate is often
used as a high-energy substrate by neighboring aerobic cells [93]. We have shown that constitutively
active STAT3 plays a key role in this switch, promoting aerobic glycolysis via hypoxia-inducible
factor 1, α subunit (HIF1α) transcriptional induction, and down regulating mitochondrial activity
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via the HIF1α-independent modulation of nuclear genes encoding for electron transport complexes
(ETC) [94]. This metabolic switch enhances lactate production and leads to a decreased production of
ROS, protecting cells from apoptosis and senescence, and is relevant in cancer cells displaying STAT3
constitutive activity, as shown by the reduced glucose intake of tumors xenografted in mice treated
with a STAT3 inhibitor [94]. Moreover, STAT3-mediated aerobic glycolysis contributes to the ability of
constitutively active STAT3 to act as a hit in tumor transformation [95].
Intriguingly, as mentioned above, STAT3 was described in a number of cell types to be able to
localize to mitochondria, where its SP form is able to regulate the respiratory and signaling functions of
this organelle [37,96–99]. By immunoprecipitation, STAT3 was demonstrated to physically interact with
distinct ETC, in primis complex 1 [37,96,100]. Accordingly, despite the lack of a classical amino-terminal
mitochondrial targeting sequence, STAT3 is associated with the inner mitochondrial membrane and
the mitochondrial matrix, as shown by the protease experiments [37]. It was suggested that STAT3
mitochondrial import may be mediated by Gene associated with Retinoid Interferon induced cell
Mortality (GRIM) 19 [100] and/or by the heat shock protein 22, at least in cardiomyocytes [101].
Moreover, STAT3 has been shown to associate with the chaperone TOM20, leading to the hypothesis
that either TOM20 or TOM70 are involved in its mitochondrial transport [74,102,103].
Mitochondrial STAT3 functions (recently reviewed by Garama and Gough [74] and by
Rincon and Pereira [26]), are in line with its pro-oncogenic activities, contributing to cell survival
under specific stress conditions such as the ischemic heart, or downstream of Ras-mediated
transformation [37,96,104]. Specifically, mitochondrial STAT3 was shown, possibly via the interaction
with ETCI and II, to preserve optimal ETC activity, increase membrane polarization and ATP
production, and enhance the activity of lactate dehydrogenase. As a consequence, aerobic glycolysis is
induced and ROS production decreased [96,100,104–107]. In addition to these actions, which contribute
to the maintenance of energy balance under stress, protection from apoptosis could also be triggered
by the inhibition of the mitochondrial permeability transition pore (MPTP) opening, which in
turn may be explained by its ability to interact with cyclophilin D [102] (Figure 1). Indeed,
opening of the MPTP, which is crucial for the release of pro-apoptotic peptides that initiates the
intrinsic apoptotic program, is triggered by the stress conditions related to the excessive release of
calcium from the endoplasmic reticulum, resulting in excessive or prolonged Ca2+ fluxes into the
mitochondrion [108], and the STAT3 null cells were shown to require lower Ca2+ concentration to
initiate MPTP opening [102]. Increased ETC activity is usually associated to increased ROS production,
and therefore the observation of reduced mitochondrial ROS triggered by STAT3 concomitantly
to increased ETC activity, confirmed in many cell types, including astrocytes and hematopoietic
cells [97–99], appears counterintuitive. Mercedes Rincon and colleagues have proposed a brilliant
answer to this conundrum, demonstrating that the activation of CD4+ T cell by IL-6 requires
mitochondrial STAT3 and coincides with the formation of ET super complexes, which, by optimizing
coupling, are known to reduce electron leakage [99]. IL-6 treatment increases the STAT3 concentration
in the mitochondrion, which correlates with physical interaction with the super complexes, suggesting
a role for STAT3 in their formation/function. Under these conditions, enhanced ETC activity increased
the polarization of the mitochondrial membrane but, strikingly, did not trigger increase ATP production.
Rather, it led to increased mitochondrial Ca2+ levels. In turn, these were required to ensure the
prolonged stimulation of IL-4 production via the activation of the nuclear factor for activated T-cells
(NFAT) and the induction of effector Th2 T-cells from naïve CD4+ T-cells [99]. Mitochondrial STAT3
may also contribute to the control of ROS levels via the enhanced synthesis of ROS scavengers, as it
was shown that it can increase, via a still uncharacterized mechanism, the levels of the major cellular
ROS scavenger glutathione, and indeed the pharmacological inhibition of GSH synthesis led to ROS
accumulation, DNA damage, and cell death in STAT3-sufficient cell lines transformed by Ras [109].
SP, which was shown to occur downstream of Ras-activated MAP kinases [37,110] and of PKCε
in keratinocytes upon TPA or EGF treatment [107,111], is believed to be required for most, if not
all, the mitochondrial functions of STAT3. SP is however not required for STAT3 mitochondrial
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translocation. Rather, K87 acetylation triggered by insulin signaling was proposed to be required for
STAT3 to translocate to mitochondria, where it interacts with pyruvate dehydrogenase complex E1
resulting in an increased membrane potential and ATP production [77]. On the other hand, despite not
being required for the above-described functions, mitochondrial STAT3 is also amply phosphorylated
on Y705 [99,107,111]. Several observations point toward a role also for YP STAT3 in this organelle.
For example, BCL2 overexpression recruits YP, but not SP, and STAT3 to mitochondria in the human
colon cancer cell line HCT116, where it leads to increased O2-production enhancing survival [112].
Additionally, an abundant signal for YP STAT3 can be observed in the mitochondrial fractions from
both the activated CD4+ T-cells and leukemia inhibitory factor (LIF)-stimulated ES cells [99,107].
As both YP and SP are detected on mitochondrial STAT3, it would be relevant to determine whether
both modifications coexist on the same molecule, or whether separate subsets of STAT3, either YP or
SP, exist. YP is likely to be involved in the STAT3 transcriptional activities that have been demonstrated
to occur within mitochondria. Indeed, STAT3 can bind to mitochondrial DNA in both keratinocytes
and ESCs. In keratinocytes, STAT3 appears to act as a transcriptional repressor by interacting with
the master mitochondrial transcription factor TFAM to down-regulate respiratory chain genes [111],
leading, in contrast to all other described mitochondrial functions, to reduced ETC activity. Different is
the situation in ES cells, where STAT3 acts as a transcriptional activator of transcriptional units encoding
for ETC subunits, enhancing their expression levels and leading to increased complexes assembly
and improved respiration, in turn a required to support ESCs proliferative activity downstream of
LIF [107]. The authors conclude that this activity explains the requirement for LIF stimulation and
STAT3 activity to maintain ESCs pluripotency.
Many reports suggest that several known STAT3 pro-oncogenic activities previously ascribed
solely to YP involve SP instead. Originally, SP STAT3 was reported to sustain the tumor transformation
of MEF cells downstream of Harvey rat sarcoma virus oncogene (H-RAS) [37]. Additionally, the SP
STAT3-mediated enhancement of ETC activity, mitochondrial membrane polarization, and ATP
production were also shown to be involved in K-RAS-driven myeloid malignancy and in the
development of pancreatic cancer [37,103,105,110]. Moreover, SP STAT3 mediates the in vivo growth
and metastatic potential of murine mammary tumor 4T1 cells by increasing complex I coupling
and reducing ROS production [106]. In this vein, it has been shown that the STAT3 inhibitor
phospho-valproic acid can also inhibit the mitochondrial STAT3 functions, and is able to decrease the
STAT3 mitochondrial localization, correlating with the impaired growth of human pancreatic tumor
xenografts [113]. Increased pituitary tumorigenesis has also been observed following expression of
an FGFR form carrying the R388 single nucleotide polymorphism in pituitary cells, correlating with
SP-STAT3 accumulation in mitochondria and enhanced cytochrome c oxidase activity [114].
5. Not only Nucleus and Mitochondrion: The Endoplasmic Reticulum Takes Centre Stage
MEF cells expressing constitutively active STAT3, in addition to a steady-state reduction of the
mitochondrial membrane potential and of ETC protein levels, also featured reduced mitochondrial
activation in response to ATP, assessed as a reduced flux of Ca2+ ions into the mitochondria [94].
Ca2+ homeostasis and the regulation of its fluxes between different subcellular compartments
are of fundamental importance for the control of many cellular functions, including life/death
decisions [115]. The endoplasmic reticulum (ER) is the major intracellular Ca2+ storage
compartment [116]. ER calcium contents are regulated by the equilibrium between the coordinated
activities of Ca2+ pumps such as the SERCAs, which trigger ER Ca2+ entry, and of Ca2+ channels
activated by the second messenger IP3 downstream of many different extracellular signals [117],
the inositol 1,4,5-triphosphate receptors (IP3R). The entry of Ca2+ in the mitochondrial matrix regulates
the activation of mitochondrial respiration, as the Ca2+ concentration is rate-limiting for the function
of several enzymes of the Krebs cycle [118]. However, the continuous or excessive release of Ca2+ at
the mitochondrial associated membranes (MAMs) [119], and specialized ER structures formed by the
apposition of ER and mitochondrial membranes, can lead to mitochondrial Ca2+ overload, triggering
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the opening of the MPTP and the initiation of the intrinsic apoptotic program [120,121] (Figure 2).
Therefore, the abundance and activity of the IP3Rs and in particular of IP3R3, which is preferentially
involved in transmitting apoptotic Ca2+ signals to mitochondria [122], is a key factor regulating the
sensitivity of cells to those apoptotic stimuli known to trigger Ca2+-mediated cell death, like H2O2
and menadione [123]. It is thus not surprising that the ER-mitochondria interface acts as a signaling
hub for the activity of growth factors, oncogenes, and oncosuppressors [118,124]. Indeed, AKT, PTEN,
PML, and BCL-2 have all been shown to regulate IP3R3 activity and be in abundance in the MAMs,
leading to an altered sensitivity to apoptosis [123,125–127].
With this in mind, we decided to assess whether STAT3 could somehow alter Ca2+ release from
the ER, and indeed we observed a significantly reduced ER Ca2+ content and release in MEF cells [128].
Importantly, the silencing of STAT3 in the STAT3-dependent MDA-MB-468 and -231 significantly
increased the Ca2+ content and release, while not affecting at all of the MDA-MB-453 or T47D cells,
which do not display activated STAT3. Increased Ca2+ release upon STAT3 silencing occurred, only in
the STAT3-dependent cells, also upon H2O2 or menadione treatment, correlating with a significant
increased sensitivity to apoptotic cell death.
A possible explanation of how STAT3 could regulate ER Ca2+ homeostasis came from the observation
that this factor, both phosphorylated on Y705 and on S727 abundantly, localizes to the ER and MAMs,
where it physically interacts with the IP3R3 Ca2+ channel. Although neither SP nor YP are required for
either ER localization or IP3R3 interaction, it is the phosphorylation on S727 that appears to play the
regulatory role, as MEF cells expressing a STAT3 mutated on S727, but not a WT or Y-F mutant, displayed
excessive Ca2+ release and apoptotic cell death upon H2O2 or menadione treatment. Finally, we could
demonstrate that ER STAT3 acts by facilitating IP3R3 proteasomal degradation, likely via the ubiquitin
E3 ligase FBXL2 [127]. Indeed, IP3R3 degradation is impaired when cells are either silenced for STAT3
or only express a S-A mutant [128] (Figure 2). These observations explain why tumors often displaying
STAT3 constitutive activation, such as mammary tumors belonging to the basal-like subtype, display an
inverse correlation between the phospo-STAT3 and IP3R3 protein levels [128].
Figure 2. STAT3 role in the endoplasmic reticulum (ER). See text for details and references.
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The well-known anti-apoptotic functions of STAT3, so far known to be based on the transcriptional
activation of anti-apoptotic genes in the nucleus and on the maintenance of ETC activity in the
mitochondrion, now include also its activities at the ER and MAMs, via IP3R3 degradation and
modulation of Ca2+ fluxes.
6. Conclusions
STAT3 has long been considered a pleiotropic factor, due to its multiple activators and its ability
to regulate the transcription of different target genes under different conditions. In the past few years,
it became clear that STAT3 multifaceted functions were even underestimated, as this factor acts in an
unconventional way outside from the nucleus, regulating the functions of mitochondria and the ER
independently of its transcriptional activity (Figure 1). Although much has been discovered about
these non-canonical functions of STAT3, our understanding of the molecular mechanisms involved is
still incomplete. All of these activities contribute to the known STAT3 physiological and pathological
functions, and this knowledge complicates the already difficult task of targeting STAT3 for therapeutic
purposes. The question of which activity/activities should be targeted under which conditions needs
to be asked. Moreover, the altered equilibrium between different STAT3 forms that could be caused by
the specific inhibition of one of them needs to be taken into account.
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Abbreviations
G-CSF Granulocyte colony-stimulating factor
EGF Epidermal growth factor
PDGF Platelet-derived growth factor
K-RAS Kirsten rat sarcoma viral oncogene homolog
TPA 12-O-Tetradecanoylphorbol-13-acetate
DSS Dextran Sodium Sulfate
DMBA 7,12-Dimethylbenz[a]-anthracene
AOM Azoxymethane
GAS Gamma interferon activation site
FAK Focal adhesion kinase
NAD Nicotinamide adenine dinucleotide
ROS Reactive oxygen species
IGF1 Insulin-like growth factor 1
HIF1α Hypoxia-inducible factor 1, α subunit
LIF Leukemia inhibitory factor
TFAM Mitochondrial transcription factor A
H-RAS Harvey rat sarcoma virus oncogene
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